{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:35:20Z","timestamp":1776929720251,"version":"3.51.2"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejphar.2020.173635","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T21:59:24Z","timestamp":1602626364000},"page":"173635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist"],"prefix":"10.1016","volume":"890","author":[{"given":"Cristina","family":"Cosi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s L.","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginetta","family":"Collo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cavalleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Heusler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Leriche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Gaudoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Sokoloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Gatti-McArthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173635_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF00174864","article-title":"Dopamine neurochemical profile of atypical antipsychotics reS.E.M.bles that of D-1 antagonists","volume":"338","author":"Altar","year":"1988","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/MCB.00916-15","article-title":"A GIPC1-palmitate switch modulates dopamine Drd3 receptor trafficking and signaling","volume":"36","author":"Arango-Lievano","year":"2016","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2020.173635_bib3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1017\/S1461145709991222","article-title":"F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity","volume":"13","author":"Assie","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00210-006-0092-z","article-title":"In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles","volume":"373","author":"Assie","year":"2006","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejphar.2009.02.001","article-title":"F15063, a potential antipsychotic with dopamine D2\/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release","volume":"607","author":"Assie","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.105.087163","article-title":"Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain","volume":"315","author":"Assie","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173635_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.neuropharm.2013.02.024","article-title":"Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety","volume":"70","author":"Auclair","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.nbd.2014.12.008","article-title":"Dopaminergic denervation switches dopamine D3 receptor signaling and disrupts its Ca(2+) dependent modulation by CaMKII and calmodulin in striatonigral projections of the rat","volume":"74","author":"Avalos-Fuentes","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2020.173635_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FBP.0b013e3280ae6c96","article-title":"Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2\/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics","volume":"18","author":"Bardin","year":"2007","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib10","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1038\/s41467-018-05382-3","article-title":"Role of VTA dopamine neurons and neuroligin 3 in sociability traits related to nonfamiliar conspecific interaction","volume":"9","author":"Bariselli","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2020.173635_bib11","doi-asserted-by":"crossref","first-page":"E1382","DOI":"10.1073\/pnas.1525586113","article-title":"Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning","volume":"113","author":"Barre","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2020.173635_bib12","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41386-019-0355-2","article-title":"Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia","volume":"44","author":"Bitter","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061341","article-title":"Receptor(-)Receptor interactions in multiple 5-ht1a heteroreceptor complexes in raphe-hippocampal 5-HT transmission and their relevance for depression and its treatment","volume":"23","author":"Borroto-Escuela","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2020.173635_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0014-2999(99)00916-4","article-title":"Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice","volume":"391","author":"Boulay","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib15","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1021\/jm501119j","article-title":"Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies","volume":"57","author":"Brindisi","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173635_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2006.01.027","article-title":"Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase","volume":"534","author":"Bruins Slot","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neuropharm.2007.05.006","article-title":"Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1\/2 activation","volume":"53","author":"Bruins Slot","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/S109285291900083X","article-title":"The role of dopamine D3 receptors in the mechanism of action of cariprazine","volume":"25","author":"Calabrese","year":"2020","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejphar.2020.173635_bib19","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1021\/acs.jmedchem.8b01096","article-title":"Synthesis and biological evaluation of fused tricyclic heterocycle piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics","volume":"61","author":"Cao","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173635_bib20","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0006-8993(00)03067-5","article-title":"Dopamine and 5-HT turnover are increased by the mGlu 2\/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum","volume":"887","author":"Cartmell","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2020.173635_bib22","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","article-title":"Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling","volume":"23","author":"Cavalleri","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2020.173635_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1042\/AN20120013","article-title":"Dopamine D2 receptor-mediated Akt\/PKB signalling: initiation by the D2S receptor and role in quinpirole-induced behavioural activation","volume":"4","author":"Chen","year":"2012","journal-title":"ASN Neuro"},{"key":"10.1016\/j.ejphar.2020.173635_bib24","doi-asserted-by":"crossref","first-page":"4196961","DOI":"10.1155\/2018\/4196961","article-title":"Ropinirole and pramipexole promote structural plasticity in human iPSC-derived dopaminergic neurons via BDNF and mTOR signaling","volume":"2018","author":"Collo","year":"2018","journal-title":"Neural Plast."},{"key":"10.1016\/j.ejphar.2020.173635_bib25","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/WNR.0000000000001131","article-title":"(2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans","volume":"29","author":"Collo","year":"2018","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejphar.2020.173635_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/WNR.0000000000001185","article-title":"Ketamine increases the expression of GluR1 and GluR2 alpha-amino-3-hydroxy-5-methy-4-isoxazole propionate receptor subunits in human dopaminergic neurons differentiated from induced pluripotent stem cells","volume":"30","author":"Collo","year":"2019","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejphar.2020.173635_bib27","article-title":"Ranking antipsychotics for efficacy and safety in schizophrenia","author":"Correll","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ejphar.2020.173635_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00213-002-1043-0","article-title":"Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors","volume":"162","author":"Cussac","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ejphar.2014.06.011","article-title":"Examining dopamine D3 receptor occupancy by antipsychotic drugs via [3H]7-OH-DPAT ex vivo autoradiography and its cross-validation via c-fos immunohistochemistry in the rat brain","volume":"740","author":"Davoodi","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib30","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/mol.119.115998","article-title":"Innovative bioluminescence resonance energy transfer assay reveals differential agonist-induced D2 receptor intracellular trafficking and arrestin-3 recruitment","volume":"96","author":"De Vries","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0022-3565(25)22267-4","article-title":"Dopamine D2 receptors labeled with [3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity","volume":"250","author":"Dewar","year":"1989","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173635_bib32","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1038\/s41598-017-05633-1","article-title":"Expansion of human midbrain floor plate progenitors from induced pluripotent stem cells increases dopaminergic neuron differentiation potential","volume":"7","author":"Fedele","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.173635_bib33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41598-018-19345-7","article-title":"Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs","volume":"8","author":"Ferruz","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.173635_bib34","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.euroneuro.2014.11.021","article-title":"The D3 dopamine receptor: from structural interactions to function","volume":"25","author":"Fiorentini","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejphar.2020.173635_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2019.01.015","article-title":"The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors","volume":"58","author":"Fleischhacker","year":"2019","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.ejphar.2020.173635_bib36","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.euroneuro.2014.11.013","article-title":"Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists","volume":"25","author":"Furman","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejphar.2020.173635_bib37","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1021\/acsmedchemlett.8b00229","article-title":"New dopamine D3-selective receptor ligands containing a 6-Methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol motif","volume":"9","author":"Gadhiya","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2020.173635_bib38","article-title":"A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia","author":"Girgis","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pharep.2017.05.007","article-title":"The antipsychotic-like effects in rodents of YQA31 involve dopamine D3 and 5-HT1A receptor","volume":"69","author":"Gou","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2020.173635_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00210-012-0806-3","article-title":"Dopamine D(3) receptor antagonism--still a therapeutic option for the treatment of schizophrenia","volume":"386","author":"Gross","year":"2013","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0893-133X(98)00066-9","article-title":"Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons","volume":"20","author":"Gurevich","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122519","article-title":"Molecular mechanisms of GPCR signaling: a structural perspective","volume":"18","author":"Gurevich","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2020.173635_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/10799893.2015.1069845","article-title":"Agonist stimulation at human mu opioid receptors in a [(35)S]GTPgammaS incorporation assay: observation of \"bell-shaped\" concentration-response relationships under conditions of strong receptor G protein coupling","volume":"36","author":"Heusler","year":"2016","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.ejphar.2020.173635_bib44","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.134.3483.943","article-title":"Progressive ratio as a measure of reward strength","volume":"134","author":"Hodos","year":"1961","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173635_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pbb.2015.09.011","article-title":"Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement","volume":"138","author":"Huang","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2020.173635_bib46","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2020.173635_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173635_bib48","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.neuroscience.2017.01.017","article-title":"Deficits in cognitive flexibility induced by chronic unpredictable stress are associated with impaired glutamate neurotransmission in the rat medial prefrontal cortex","volume":"346","author":"Jett","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2020.173635_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nn.4170","article-title":"Stimulus-specific combinatorial functionality of neuronal c-fos enhancers","volume":"19","author":"Joo","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173635_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnmol.2015.00017","article-title":"Suppression of NMDA receptor function in mice prenatally exposed to valproic acid improves social deficits and repetitive behaviors","volume":"8","author":"Kang","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173635_bib51","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173635_bib52","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1046\/j.1471-4159.1994.63030972.x","volume":"63","author":"Karoum","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2020.173635_bib53","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11753","article-title":"Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial","volume":"79","author":"Keefe","year":"2018","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.ejphar.2020.173635_bib54","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173635_bib55","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/0006-2952(85)90778-6","article-title":"Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain","volume":"34","author":"Kohler","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.brainresbull.2016.03.013","article-title":"Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats","volume":"124","author":"Kumar","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejphar.2020.173635_bib57","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1021\/acs.jmedchem.6b01688","article-title":"Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 receptor (D3R)","volume":"60","author":"Kumar","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173635_bib58","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00429-012-0383-8","article-title":"Molecular characterization of individual D3 dopamine receptor-expressing cells isolated from multiple brain regions of a novel mouse model","volume":"217","author":"Li","year":"2012","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.ejphar.2020.173635_bib59","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/pr.107.00107","article-title":"Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection","volume":"60","author":"Lieberman","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2020.173635_bib60","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jmgm.2018.10.013","article-title":"3D-QSAR studies of D3R antagonists and 5-HT1AR agonists","volume":"86","author":"Ma","year":"2019","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejphar.2020.173635_bib61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0028-3908(86)90040-7","article-title":"Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs","volume":"25","author":"Magnusson","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0014-2999(02)01896-4","article-title":"Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect","volume":"447","author":"Marchese","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2020.173635_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120286","article-title":"Effect of dopaminergic D1 receptors on plasticity is dependent of serotoninergic 5-HT1A receptors in L5-pyramidal neurons of the prefrontal cortex","volume":"10","author":"Meunier","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173635_bib65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cellsig.2017.07.003","article-title":"Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds","volume":"41","author":"Moritz","year":"2018","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejphar.2020.173635_bib66","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.schres.2008.07.005","article-title":"Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine","volume":"105","author":"Natesan","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2020.173635_bib67","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib68","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2020.173635_bib69","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.bjp.0707158","article-title":"F15063, a potential antipsychotic with D2\/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile","volume":"151","author":"Newman-Tancredi","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib71","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)\/alpha(2)-adrenoceptor","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173635_bib72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0304-3940(95)11381-6","article-title":"Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation by monoamine oxidase inhibitor in the rat","volume":"188","author":"Obata","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2020.173635_bib73","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1039\/C7MD00281E","article-title":"Development of selective agents targeting serotonin 5HT1A receptors with subnanomolar activities based on a coumarin core","volume":"8","author":"Ostrowska","year":"2017","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejphar.2020.173635_bib74","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s11064-006-9135-6","article-title":"Characteristics of binding of [3H]WAY100635 to rat hippocampal membranes","volume":"31","author":"Parkel","year":"2006","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejphar.2020.173635_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/1179573517726335","article-title":"Abnormalities of dopamine D3 receptor signaling in the diseased brain","volume":"9","author":"Prieto","year":"2017","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.ejphar.2020.173635_bib76","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neuropharm.2014.10.030","article-title":"Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA\/2J mice: II. Effects of D3 dopamine receptor selective compounds","volume":"93","author":"Rangel-Barajas","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib77","doi-asserted-by":"crossref","first-page":"9905","DOI":"10.1021\/acs.jmedchem.7b01248","article-title":"Highly selective dopamine D3 receptor antagonists with arylated diazaspiro alkane cores","volume":"60","author":"Reilly","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173635_bib78","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjp.0703139","article-title":"Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex","volume":"129","author":"Sakaue","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib79","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.npp.1300518","article-title":"Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism","volume":"30","author":"Schneider","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173635_bib81","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","article-title":"Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes","volume":"27","author":"Silvestre","year":"2005","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib82","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.biopsych.2013.11.023","article-title":"Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition","volume":"76","author":"Simpson","year":"2014","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2020.173635_bib83","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-019-05387-w","article-title":"Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [(11)C]-(+)-PHNO","volume":"237","author":"Slifstein","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib84","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0922-4106(92)90107-7","article-title":"Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor","volume":"225","author":"Sokoloff","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib85","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173635_bib86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00210-012-0797-0","article-title":"Direct and indirect interactions of the dopamine D(3) receptor with glutamate pathways: implications for the treatment of schizophrenia","volume":"386","author":"Sokoloff","year":"2013","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib87","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fphar.2015.00162","article-title":"The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory","volume":"6","author":"Stiedl","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib88","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/aps.2015.105","article-title":"Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia","volume":"37","author":"Sun","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2020.173635_bib89","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0026-895X(25)08761-9","article-title":"Interpretation of binding curves obtained with high receptor concentrations: practical aid for computer analysis","volume":"47","author":"Swillens","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173635_bib90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neuint.2019.04.008","article-title":"Blonanserin ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia","volume":"128","author":"Takeuchi","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2020.173635_bib91","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00213-014-3780-2","article-title":"A systematic microdialysis study of dopamine transmission in the accumbens shell\/core and prefrontal cortex after acute antipsychotics","volume":"232","author":"Tanda","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2020.173635_bib92","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"Glutamate hypothesis in schizophrenia","volume":"73","author":"Uno","year":"2019","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173635_bib93","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jneumeth.2018.05.016","article-title":"The use of microwave irradiation for quantitative analysis of neurotransmitters in the mouse brain","volume":"307","author":"Wasek","year":"2018","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.ejphar.2020.173635_bib94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1523\/JNEUROSCI.21-01-00035.2001","article-title":"Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition","volume":"21","author":"Wayment","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173635_bib95","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","article-title":"Pathway-specific dopamine abnormalities in schizophrenia","volume":"81","author":"Weinstein","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2020.173635_bib96","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.schres.2019.01.023","article-title":"Intrinsic mesocorticolimbic connectivity is negatively associated with social amotivation in people with schizophrenia","volume":"208","author":"Xu","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2020.173635_bib97","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/acschemneuro.6b00162","article-title":"Reformulating a pharmacophore for 5-HT2A serotonin receptor antagonists","volume":"7","author":"Younkin","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173635_bib98","doi-asserted-by":"crossref","first-page":"35842","DOI":"10.1074\/jbc.M611758200","article-title":"Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors","volume":"282","author":"Zapata","year":"2007","journal-title":"J. Biol. Chem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920307275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920307275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:47:03Z","timestamp":1757976423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920307275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":98,"alternative-id":["S0014299920307275"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173635","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173635"}}